1 May 2026Oral drugsSource update: November 2022
Tenofovir disoproxil fumarate = TDF oral
Tenofovir guidance for HIV infection and chronic hepatitis B, with renal and bone precautions.
Prescription under medical supervision
This guide page is for structured reference only and does not replace a clinician, pharmacist, or emergency review. Dose choice, route choice, interactions, and safety decisions still need professional judgment.
Therapeutic action
Antiretroviral, HIV nucleotide reverse transcriptase inhibitor.
Indications
- HIV infection with or without chronic hepatitis B coinfection, in combination with other antiretrovirals.
- Chronic hepatitis B without HIV coinfection, in monotherapy.
Forms and strengths
- 300 mg tablet, equivalent to 245 mg of tenofovir disoproxil.
Dose
- Child 35 kg and over and adult: 300 mg once daily.
Duration
Depending on the efficacy and tolerance of tenofovir.
Contra-indications, adverse effects, precautions
- Administer with caution and monitor use in patients with renal impairment or osteoporosis. In the event of deterioration of renal function, switch to another antiretroviral.
- Avoid combination, or closely monitor renal function, with nephrotoxic drugs such as aminoglycosides, amphotericin B, pentamidine, and NSAIDs.
- May cause gastrointestinal disturbances, dizziness, fatigue, skin rash, renal impairment, bone loss, and pancreatitis.
- Pregnancy: no contra-indication.
Source
MSF Essential drugs practical guidelines (January 2026)
This page reproduces the structured reference information for this batch while leaving out the Storage and Remarks sections.
Rate this guide
Be the first to rate this guide.